Trends in real-world clinical outcomes among patients (pts) with metastatic pancreatic adenocarcinoma (mPDAC) treated with liposomal irinotecan based regimens in the United States (US).

Jim M. Koeller,Paul Cockrum,Bruce Belanger,Frank A. Corvino,Andy Surinach,George P. Kim

Trends in real-world clinical outcomes among patients (pts) with metastatic pancreatic adenocarcinoma (mPDAC) treated with liposomal irinotecan based regimens in the United States (US).

2020

Jim M. Koeller
Paul Cockrum
Bruce Belanger
Frank A. Corvino
Andy Surinach
George P. Kim

e16751Background: The NAPOLI-1 study, a randomized phase 3 study in pts with mPDAC previously treated with gemcitabine-based therapy, demonstrated an improvement in overall survival (OS) with lipos...

Keywords:

Oncology
Internal medicine
Liposomal Irinotecan
Pathology
Metastatic Pancreatic Adenocarcinoma
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations